Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2300070437Phase 3Not yet recruiting
Phase 3, randomised, double-blind trial of ropivacaine and lidocaine in postoperative pain (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Sufentanil consumption 48 hours after surgery. Planned start May 2023; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2300070437.